Login / Signup

Rotational thrombelastometry (ROTEM) improves hemostasis assessment compared to conventional coagulation test in ACLF and Non-ACLF patients.

Jessica SeeßleJan LöhrMarietta KirchnerJosefin MichaelisUta Merle
Published in: BMC gastroenterology (2020)
For assessing hemostasis in Non-ACLF and ACLF patients the underlying dataset shows advantages of ROTEM over CCT. A10 and MCF represent suitable prognostic parameters in predicting bleeding events in ACLF group.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • atrial fibrillation
  • patient reported
  • breast cancer cells